GGrantIndex
← Leaderboards

Brian Jesse Debosch

Washington University

$7,536,271
Attributed
$7,536,271
Total exposure
8
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.7M · FY201825
$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,536,271 · 8

By mechanism

R01$6,221,036 · 3
P30$501,547 · 3
R21$432,438 · 1
R56$381,250 · 1

Top collaborators

No co-investigators on record.

Most similar at Washington University

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Metabolism

Research focus

MetabolismSignal TransductionNon-Alcoholic Fatty Liver DiseaseHepatocytePathway InteractionsFasting GlucoseFastingLiverFatty LiverHepaticAttenuatedResponseGlucose TransportAutophagocytosisDiabetes MellitusTherapeutic EffectMouse ModelNext GenerationCardiovascular SystemInsulin ResistancePreventMimeticsDisaccharidesTrehalose

Grant awards (24)

Leveraging arginase biology against metabolic disease$440,154
R01 · FY2025 · DK · contact PI
Enrichment Program$15,442
P30 · FY2025 · DK · contact PI
Treating secondary cardiomyopathies by mimicking the adaptive hepatic glucose fasting response$612,000
R01 · FY2024 · HL · contact PI
Leveraging arginase biology against metabolic disease$416,258
R01 · FY2024 · DK · contact PI
Leveraging glucose transport and the adaptive fasting response to modulate hepatic metabolism$389,892
R01 · FY2024 · DK · contact PI
Pilot & Feasibility Program$205,217
P30 · FY2024 · DK · contact PI
Enrichment Program$30,771
P30 · FY2024 · DK · contact PI
Treating secondary cardiomyopathies by mimicking the adaptive hepatic glucose fasting response$5,050
R01 · FY2024 · HL · contact PI
Leveraging glucose transport and the adaptive fasting response to modulate hepatic metabolism$1
R01 · FY2024 · DK · contact PI
Treating secondary cardiomyopathies by mimicking the adaptive hepatic glucose fasting response$626,492
R01 · FY2023 · HL · contact PI
Leveraging arginase biology against metabolic disease$436,856
R01 · FY2023 · DK · contact PI
Leveraging glucose transport and the adaptive fasting response to modulate hepatic metabolism$404,028
R01 · FY2023 · DK · contact PI
Pilot & Feasibility Program$203,791
P30 · FY2023 · DK · contact PI
Enrichment Program$15,442
P30 · FY2023 · DK · contact PI
Treating secondary cardiomyopathies by mimicking the adaptive hepatic glucose fasting response$629,642
R01 · FY2022 · HL · contact PI
Leveraging glucose transport and the adaptive fasting response to modulate hepatic metabolism$440,186
R01 · FY2022 · DK · contact PI
Enrichment Program$15,442
P30 · FY2022 · DK · contact PI
Treating secondary cardiomyopathies by mimicking the adaptive hepatic glucose fasting response$678,171
R01 · FY2021 · HL · contact PI
Leveraging glucose transport and the adaptive fasting response to modulate hepatic metabolism$448,239
R01 · FY2021 · DK · contact PI
Enrichment Program$15,442
P30 · FY2021 · DK · contact PI
Treating secondary cardiomyopathies by mimicking the adaptive hepatic glucose fasting response$694,067
R01 · FY2020 · HL · contact PI
Biological Effects and Mechanistic Actions of the Natural Disaccharide and Dietary Supplement, Trehalose.$196,875
R21 · FY2020 · AT · contact PI
Biological Effects and Mechanistic Actions of the Natural Disaccharide and Dietary Supplement, Trehalose.$235,563
R21 · FY2019 · AT · contact PI
Leveraging glucose transport and the adaptive fasting response to modulate hepatic metabolism$381,250
R56 · FY2018 · DK · contact PI